PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma

References

• Goodman LS, Wintrobe MM, Dameshek W, et al. Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin’s disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J Am Med Assoc. 1946 Sep;21(132):126–132.
   Google Scholar
• Westin JR. Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma. Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):335–342.
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, et al. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010 May;11(5):329–341.
   PubMed Web of Science ®Google Scholar
• Clayton E, Bardi G, Bell SE, et al. A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med. 2002 Sep 16;196(6):753–763.
   PubMed Web of Science ®Google Scholar
• Jou ST, Carpino N, Takahashi Y, et al. Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol Cell Biol. 2002 Dec;22(24):8580–8591.
   PubMed Web of Science ®Google Scholar
• Okkenhaug K, Bilancio A, Farjot G, et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science. 2002 Aug 09;297(5583):1031–1034.
   PubMed Web of Science ®Google Scholar
• Ramadani F, Bolland DJ, Garcon F, et al. The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development. Sci Signal. 2010 Aug 10;3(134):ra60.
   PubMed Web of Science ®Google Scholar
• Webb LM, Vigorito E, Wymann MP, et al. Cutting edge: T cell development requires the combined activities of the p110gamma and p110delta catalytic isoforms of phosphatidylinositol 3-kinase. J Immunol. 2005 Sep 01;175(5):2783–2787.
   PubMed Web of Science ®Google Scholar
• Garcon F, Patton DT, Emery JL, et al. CD28 provides T-cell costimulation and enhances PI3K activity at the immune synapse independently of its capacity to interact with the p85/p110 heterodimer. Blood. 2008 Feb 01;111(3):1464–1471.
   PubMed Web of Science ®Google Scholar
• Janas ML, Varano G, Gudmundsson K, et al. Thymic development beyond beta-selection requires phosphatidylinositol 3-kinase activation by CXCR4. J Exp Med. 2010 Jan 18;207(1):247–261.
   PubMed Web of Science ®Google Scholar
• Ali K, Soond DR, Pineiro R, et al. Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer. Nature. 2014 Jun 19;510(7505):407–411.
   PubMed Web of Science ®Google Scholar
• Okkenhaug K, Patton DT, Bilancio A, et al. The p110delta isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells. J Immunol. 2006 Oct 15;177(8):5122–5128.
   PubMed Web of Science ®Google Scholar
• Martin AL, Schwartz MD, Jameson SC, et al. Selective regulation of CD8 effector T cell migration by the p110 gamma isoform of phosphatidylinositol 3-kinase. J Immunol. 2008 Feb 15;180(4):2081–2088.
   PubMed Web of Science ®Google Scholar
• Thomas MS, Mitchell JS, DeNucci CC, et al. The p110gamma isoform of phosphatidylinositol 3-kinase regulates migration of effector CD4 T lymphocytes into peripheral inflammatory sites. J Leukoc Biol. 2008 Sep;84(3):814–823.
   PubMed Web of Science ®Google Scholar
• Patton DT, Garden OA, Pearce WP, et al. Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells. J Immunol. 2006 Nov 15;177(10):6598–6602.
   PubMed Web of Science ®Google Scholar
• Steinbach EC, Kobayashi T, Russo SM, et al. Innate PI3K p110delta regulates Th1/Th17 development and microbiota-dependent colitis. J Immunol. 2014 Apr 15;192(8):3958–3968.
   PubMed Web of Science ®Google Scholar
• Aksoy E, Taboubi S, Torres D, et al. The p110delta isoform of the kinase PI(3)K controls the subcellular compartmentalization of TLR4 signaling and protects from endotoxic shock. Nat Immunol. 2012 Nov;13(11):1045–1054.
   PubMed Web of Science ®Google Scholar
• Koyasu S. The role of PI3K in immune cells. Nat Immunol. 2003 Apr;4(4):313–319.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Irie-Sasaki J, Jones RG, et al. Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science. 2000 Feb 11;287(5455):1040–1046.
   PubMed Web of Science ®Google Scholar
• Kaneda MM, Messer KS, Ralainirina N, et al. PI3Kgamma is a molecular switch that controls immune suppression. Nature. 2016 Nov 17;539(7629):437–442.
   PubMed Web of Science ®Google Scholar
• Abubaker J, Bavi PP, Al-Harbi S, et al. PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma. Leukemia. 2007 Nov;21(11):2368–2370.
   PubMed Web of Science ®Google Scholar
• Baohua Y, Xiaoyan Z, Tiecheng Z, et al. Mutations of the PIK3CA gene in diffuse large B cell lymphoma. Diagn Mol Pathol. 2008 Sep;17(3):159–165.
   PubMedGoogle Scholar
• Wang X, Huang H, Young KH. The PTEN tumor suppressor gene and its role in lymphoma pathogenesis. Aging (Albany NY). 2015 Dec;7(12):1032–1049.
   PubMedGoogle Scholar
• Psyrri A, Papageorgiou S, Liakata E, et al. Phosphatidylinositol 3ʹ-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin Cancer Res. 2009 Sep 15;15(18):5724–5732.
   PubMed Web of Science ®Google Scholar
• Cui W, Cai Y, Wang W, et al. Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma. J Transl Med. 2014 Jan 13;12:10.
   PubMed Web of Science ®Google Scholar
• Okkenhaug K, Graupera M, Vanhaesebroeck B. Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis, and immunotherapy. Cancer Discov. 2016 Oct;6(10):1090–1105.
   PubMed Web of Science ®Google Scholar
• Shaffer AL, Young RM, 3rd, Staudt LM. Pathogenesis of human B cell lymphomas. Annu Rev Immunol. 2012;30:565–610.
   PubMed Web of Science ®Google Scholar
• Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. 2013 Dec;34(12):592–601.
   PubMed Web of Science ®Google Scholar
• Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010 Jan 07;463(7277):88–92.
   PubMed Web of Science ®Google Scholar
• Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011 Jan 13;117(2):591–594.
   PubMed Web of Science ®Google Scholar
• Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3ʹ-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011 Sep 29;118(13):3603–3612.
   PubMed Web of Science ®Google Scholar
• Meadows SA, Vega F, Kashishian A, et al. PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood. 2012 Feb 23;119(8):1897–1900.
   PubMed Web of Science ®Google Scholar
• Herman SE, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010 Sep 23;116(12):2078–2088.
   PubMed Web of Science ®Google Scholar
• Shull AY, Noonepalle SK, Awan FT, et al. RPPA-based protein profiling reveals eIF4G overexpression and 4E-BP1 serine 65 phosphorylation as molecular events that correspond with a pro-survival phenotype in chronic lymphocytic leukemia. Oncotarget. 2015 Jun 10;6(16):14632–14645.
   PubMed Web of Science ®Google Scholar
• Paul J, Soujon M, Wengner AM, et al. Simultaneous inhibition of PI3Kdelta and PI3Kalpha induces ABC-DLBCL regression by blocking BCR-dependent and -independent activation of NF-kappaB and AKT. Cancer Cell. 2017 Jan 09;31(1):64–78.
   PubMed Web of Science ®Google Scholar
• Gockeritz E, Kerwien S, Baumann M, et al. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells. Int J Cancer. 2015 Nov 01;137(9):2234–2242.
   PubMed Web of Science ®Google Scholar
• Iyengar S, Clear A, Bodor C, et al. P110alpha-mediated constitutive PI3K signaling limits the efficacy of p110delta-selective inhibition in mantle cell lymphoma, particularly with multiple relapse. Blood. 2013 Mar 21;121(12):2274–2284.
   PubMed Web of Science ®Google Scholar
• Ten Hacken E, Burger JA. Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: implications for disease pathogenesis and treatment. Biochim Biophys Acta. 2016 Mar;1863(3):401–413.
   PubMed Web of Science ®Google Scholar
• Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014 May 29;123(22):3390–3397.
   PubMed Web of Science ®Google Scholar
• Fiorcari S, Brown WS, McIntyre BW, et al. The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. PLoS One. 2013;8(12):e83830.
   PubMed Web of Science ®Google Scholar
• Marshall NA, Galvin KC, Corcoran AM, et al. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-gamma+IL-17+ polyfunctional T cells that mediate rejection of murine tumors. Cancer Res. 2012 Feb 01;72(3):581–591.
   PubMed Web of Science ®Google Scholar
• Winkler DG, Faia KL, DiNitto JP, et al. PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364–1374.
   PubMed Web of Science ®Google Scholar
• Burris HA, Patel MR, Lanasa MC, et al. Activity of TGR-1202, a novel once-daily PI3Kδ inhibitor, in patients with relapsed or refractory hematologic malignancies [Meeting Abstract]. J Clin Oncol. 2014;32(15_suppl):2513–2513.
   PubMed Web of Science ®Google Scholar
• Viswanadha S, Gaudio E, Zucca E, et al. Dual PI3Kδ/γ inhibition by RP6530 induces apoptosis and cytotoxicity in b-lymphoma cells [Meeting Abstract]. Blood. 2013;122(21):4411–4411.
   Google Scholar
• Shin N, Koblish H, Covington M, et al. INCB050465, a novel PI3K delta inhibitor, synergizes with PIM protein kinase inhibition to cause tumor regression in a model of DLBCL [Meeting Abstract]. Cancer Research. 2015;75:2.
   Web of Science ®Google Scholar
• Cushing TD, Hao X, Shin Y, et al. Discovery and in vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kdelta inhibitors for inflammation and autoimmune disease. J Med Chem. 2015 Jan 08;58(1):480–511.
   PubMed Web of Science ®Google Scholar
• Folkes AJ, Ahmadi K, Alderton WK, et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem. 2008 Sep 25;51(18):5522–5532.
   PubMed Web of Science ®Google Scholar
• Shugg RP, Thomson A, Tanabe N, et al. Effects of isoform-selective phosphatidylinositol 3-kinase inhibitors on osteoclasts: actions on cytoskeletal organization, survival, and resorption. J Biol Chem. 2013 Dec 06;288(49):35346–35357.
   PubMed Web of Science ®Google Scholar
• Liu N, Rowley BR, Bull CO, et al. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110alpha and p110delta activities in tumor cell lines and xenograft models. Mol Cancer Ther. 2013 Nov;12(11):2319–2330.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Kahl BS, Leonard JP, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014 May 29;123(22):3406–3413.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, De Vos S, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014 Mar 13;370(11):1008–1018.
   PubMed Web of Science ®Google Scholar
• Kahl B, Byrd JC, Flinn IW, et al. Clinical safety and activity in a phase 1 Study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110δ, in patients with relapsed or refractory non-Hodgkin Lymphoma [Meeting Abstract]. Blood. 2010;116(21):1777–1777.
   Web of Science ®Google Scholar
• Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014 Mar 13;370(11):997–1007.
   PubMed Web of Science ®Google Scholar
• Sharman JP, Coutre SE, Furman RR, et al. Second interim analysis of a phase 3 study of idelalisib plus rituximab for relapsed chronic lymphocytic leukemia: efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors [Meeting Abstract]. Blood. 2014;124(21):330–330.
   Web of Science ®Google Scholar
• Zelenetz AD, Barrientos JC, Brown JR, et al. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017 Mar;18(3):297–311.
   PubMed Web of Science ®Google Scholar
• Jones JA, Robak T, Brown JR, et al. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol. 2017 Mar;4(3):e114–e126.
   PubMed Web of Science ®Google Scholar
• Coutre SE, Barrientos JC, Brown JR, et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015;56(10):2779–2786.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Nastoupil LJ, Neelapu SS, et al. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood. 2015;125(21):3357–3359.
   PubMed Web of Science ®Google Scholar
• Smith SM, Pitcher BN, Jung SH, et al. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. Lancet Haematol. 2017 Apr;4(4):e176–e182.
   PubMed Web of Science ®Google Scholar
• Lampson BL, Kasar SN, Matos TR, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016 Jul 14;128(2):195–203.
   PubMed Web of Science ®Google Scholar
• Weidner AS, Panarelli NC, Geyer JT, et al. Idelalisib-associated colitis: histologic findings in 14 patients. Am J Surg Pathol. 2015 Dec;39(12):1661–1667.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Fowler NH. Idelalisib in the management of lymphoma. Blood. 2016 Jul 21;128(3):331–336.
   PubMed Web of Science ®Google Scholar
• Dong S, Guinn D, Dubovsky JA, et al. IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. Blood. 2014 Dec 04;124(24):3583–3586.
   PubMed Web of Science ®Google Scholar
• Balakrishnan K, Peluso M, Fu M, et al. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. Leukemia. 2015 Sep;29(9):1811–1822.
   PubMed Web of Science ®Google Scholar
• Thompson R, Villegas V, Proctor J, et al. The potent PI3K-δ,γ inhibitor IPI-145 exhibits differential activity in Diffuse Large B-Cell Lymphoma (DLBCL) cell lines [Meeting Abstract]. Blood. 2013;122(21):1832–1832.
   Google Scholar
• White K, Murphy E, Faia K, et al. Combination of duvelisib with either ibrutinib or dexamethasone prevents mTOR-dependent feedback in aggressive B-cell lymphoma cell lines [Meeting Abstract]. Cancer Research. 2016;76(14 Supplement):376–376.
   Web of Science ®Google Scholar
• Wang J, Zhang V, Bell T, et al. The effects of PI3K-δ/γ inhibitor, duvelisib, in mantle cell lymphoma in vitro and in patient-derived xenograft studies [Meeting Abstract]. Blood. 2016;128(22):3016–3016.
   Web of Science ®Google Scholar
• Flinn I, Oki Y, Patel M, et al. A phase 1 evaluation of duvelisib (IPI-145), a PI3K-δ,γ inhibitor, in patients with relapsed/refractory iNHL [Meeting Abstract]. Blood. 2014;124(21):802–802.
   Web of Science ®Google Scholar
• Zinzani P, Wagner-Johnston N, Miller C, et al. DYNAMO: a phase 2 study demonstrating the clinical activity of duvelisib in patients with double-refractory indolent non-Hodgkin lymphoma [Meeting Abstract]. Hematol Oncol. 2017;35:69–70.
   PubMed Web of Science ®Google Scholar
• Patel MR, O’Brien SM, Faia K, et al. Early clinical activity and pharmacodynamic effects of duvelisib, a PI3K-δ,γ inhibitor, in patients with treatment-naïve CLL [Meeting Abstract]. J Clin Oncol. 2015;33(15_suppl):7074–7074.
   Web of Science ®Google Scholar
• O’Brien S, Patel M, Kahl BS, et al. Duvelisib (IPI-145), a PI3K-δ,γ inhibitor, is clinically active in patients with relapsed/refractory chronic lymphocytic leukemia [Meeting Abstract]. Blood. 2014;124(21):3334–3334.
   Web of Science ®Google Scholar
• Porcu P, Flinn I, Kahl BS, et al. Clinical activity of Duvelisib (IPI-145), a phosphoinositide-3-kinase-δ,γ inhibitor, in patients previously treated with Ibrutinib [Meeting Abstract]. Blood. 2014;124(21):3335–3335.
   Web of Science ®Google Scholar
• O’Brien S, Faia K, White K, et al. Early clinical activity and pharmacodynamic effects of Duvelisib, a PI3K-delta/gamma inhibitor, in patients with treatment-naive CLL [Meeting Abstract]. Haematologica. 2015;100:154–155.
   Web of Science ®Google Scholar
• Flinn I, Jäger U, Offner F, et al. DUO: a phase 3 trial of the PI3K-δ,γ inhibitor IPI-145 versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma [Meeting Abstract]. J Clin Oncol. 2014;32(15_suppl):TPS7122–TPS7122.
   Web of Science ®Google Scholar
• Casulo C, Sancho J-M, Van Eygen K, et al. Contempo: preliminary results in first-line treatment of follicular lymphoma with the oral dual PI3K-δ,γ inhibitor, Duvelisib, in combination with Rituximab or Obinutuzumab [Meeting Abstract]. Blood. 2016;128(22):2979–2979.
   Web of Science ®Google Scholar
• Flinn IW, Cherry M, Maris M, et al. Combination trial of Duvelisib (IPI-145) with Bendamustine, Rituximab, or Bendamustine/Rituximab in patients with lymphoma or chronic lymphocytic leukemia [Meeting Abstract]. Blood. 2015;126(23):3928–3928.
   Web of Science ®Google Scholar
• Davids MS, Kim HT, Gilbert E, et al. Preliminary results of a phase Ib study of Duvelisib in combination with FCR (dFCR) in previously untreated, younger patients with CLL [Meeting Abstract]. Blood. 2015;126(23):4158–4158.
   Web of Science ®Google Scholar
• Deng C, Lipstein MR, Scotto L, et al. Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kdelta and CK1epsilon in hematological malignancies. Blood. 2017 Jan 05;129(1):88–99.
   PubMed Web of Science ®Google Scholar
• Friedman DR, Lanasa MC, Brander DM, et al. Comparison of the PI3K-δ Inhibitors TGR1202 and GS-1101 in inducing cytotoxicity and inhibiting phosphorylation of Akt in CLL cells in vitro [Meeting Abstract]. Blood. 2012;120(21):3914–3914.
   Google Scholar
• Mato A, Burris HA, Flinn I, et al. Long-term follow-up of the next generation PI3K-delta Inhibitor TGR-1202 demonstrates safety and high response rates in CLL: integrated analysis of TGR-1202 monotherapy and combined with Ublituximab [Meeting Abstract]. Haematologica. 2016;101:50–51.
   Web of Science ®Google Scholar
• O’Connor OA, Flinn I, Lunning M, et al. Long-term follow-up of the next generation PI3K-delta inhibitor TGR-1202 demonstrates safety and high response rates in NHL: integrated analysis of TGR-1202 monotherapy and combined with Ublituximab [Meeting Abstract]. Haematologica. 2016;101:102–103.
   Web of Science ®Google Scholar
• Lunning MA, Vose JM, Bierman PJ, et al. Combination of TGR-1202, Ublituximab, and Bendamustine is safe and highly active in patients with advanced DLBCL and follicular lymphoma [Meeting Abstract]. Hematol Oncol. 2017;35:266–267.
   Google Scholar
• De Rooij MF, Kuil A, Kater AP, et al. Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy. Blood. 2015 Apr 02;125(14):2306–2309.
   PubMed Web of Science ®Google Scholar
• Davids MS, Kim HT, Nicotra A, et al. Updated results of a multicenter phase I/Ib study of TGR-1202 in combination with Ibrutinib in patients with relapsed or refractory MCL or CLL [Meeting Abstract]. Hematol Oncol. 2017;35:54–55.
   PubMed Web of Science ®Google Scholar
• Nastoupil L, Lunning MA, Vose JM, et al. Chemo-free triplet combination of TGR-1202, Ublituximab, and Ibrutinib is well tolerated and highly active in patients with advanced CLL and NHL [Meeting Abstract]. Hematol Oncol. 2017;35:112–113.
   Google Scholar
• Gaudio E, Kwee I, Spriano F, et al. The phosphatidylinositol-3-kinase (PI3K) inhibitor (i) copanlisib is active in preclinical models of B-cell lymphomas as single agent and in combination with conventional and targeted agents including venetoclax and palbociclib [Meeting Abstract]. Cancer Research. 2017;77(13 Supplement):154–154.
   Google Scholar
• Patnaik A, Appleman LJ, Tolcher AW, et al. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin’s lymphomas. Ann Oncol. 2016 Oct;27(10):1928–1940.
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, Gorbatchevsky I, Hiemeyer F, et al. CHRONOS-2: a randomized, double-blind phase III study of phosphatidylinositol-3 kinase alpha/delta inhibitor copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin’s lymphoma (iNHL) [Meeting Abstract]. Cancer Research. 2015;75(15Supplement):CT212–CT212.
   Web of Science ®Google Scholar
• Dreyling M, Morschhauser F, Bouabdallah K, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017;28:2169–2178.
   Web of Science ®Google Scholar
• Dreyling M, Santoro A, Mollica L, et al. Copanlisib in patients with relapsed or refractory indolent B-cell lymphoma (CHRONOS-1) [Meeting Abstract]. Hematol Oncol. 2017;35:119–120.
   Google Scholar
• Lenz G, Hawkes E, Verhoef G, et al. Clinical outcomes and molecular characterization from a phase II study of Copanlisib in patients with relapsed or refractory diffuse large B cell lymphoma [Meeting Abstract]. Hematol Oncol. 2017;35:68–69.
   Google Scholar
• Carlo-Stella C, Barde P, Delarue R, et al. Safety and clinical activity of RP6530, a Dual PI3Kδ/γ inhibitor, in patients with advanced hematologic malignancies: final analysis of a phase i multi-center study [Meeting Abstract]. Hematol Oncol. 2017;35:263–263.
   Google Scholar
• Carlo-Stella C, Delarue R, Barde PJ, et al. Clinical activity and safety of RP6530, a Dual PI3Kδ/γ Inhibitor, in patients with advanced hematologic malignancies: final analysis of a phase 1 multicenter study [Meeting Abstract]. Blood. 2016;128(22):3011–3011.
   PubMed Web of Science ®Google Scholar
• Caimi P, Ramchandren R, Phillips TJ, et al. Ongoing phase 1/2 study of INCB050465, a selective PI3Kδ Inibitor, for the treatment of patients with relapsed/refractory B-cell malignancies (CITADEL-101) [Meeting Abstract]. Hematol Oncol. 2017;35:268–268.
   Google Scholar
• Coleman M, Forero-Torres A, Ribrag V, et al. Phase 2 study of the safety and efficacy of INCB050465 in patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL) (CITADEL-202) [Meeting Abstract]. J Clin Oncol. 2017;35(15_suppl):TPS7579–TPS7579.
   Google Scholar
• Coleman M, Salar A, Munoz J, et al. Phase 1 study of the safety and efficacy of INCB050465 combined with obinutuzumab and bendamustine for relapsed or refractory (R/R) follicular lymphoma (FL) (CITADEL-102) [Meeting Abstract]. J Clin Oncol. 2017;35(15_suppl):TPS7578–TPS7578.
   Google Scholar
• Glenn M, Mato AR, Allgood SD, et al. First-in-human study of AMG 319, a highly selective, small molecule inhibitor of PI3Kδ, in adult patients with relapsed or refractory lymphoid malignancies [Meeting Abstract]. Blood. 2013;122(21):678–678.
   Web of Science ®Google Scholar
• Kater A, Tonino S, Kersten M, et al. Interim analysis of a phase 1B study evaluating the safety of GS-9820, a second generation PI3K-delta inhibitor, in relapsed/refractory lymphoid malignancies [Meeting Abstract]. Haematologica. 2015;100:458–458.
   PubMed Web of Science ®Google Scholar
• Garcia-Martinez JM, Wullschleger S, Preston G, et al. Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice. Br J Cancer. 2011 Mar 29;104(7):1116–1125.
   PubMed Web of Science ®Google Scholar
• Sarker D, Ang JE, Baird R, et al. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2015 Jan 01;21(1):77–86.
   PubMed Web of Science ®Google Scholar
• Huang S, Nastoupil LJ, Guo H, et al. Pre-clinical evaluation of the PI3K-p110β/δ Inhibitor KA2237 in mantle cell lymphoma [Meeting Abstract]. Blood. 2016;128(22):1837–1837.
   Google Scholar
• Zelenetz AD, Lamanna N, Kipps TJ, et al. A phase 2 study of Idelalisib monotherapy in previously untreated patients ≥65 years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) [Meeting Abstract]. Blood. 2014;124(21):1986–1986.
   Web of Science ®Google Scholar
• O’Brien SM, Lamanna N, Kipps TJ, et al. A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia. Blood. 2015 Dec 17;126(25):2686–2694.
   PubMed Web of Science ®Google Scholar
• Mato AR, Hill BT, Lamanna N, et al. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Ann Oncol. 2017 May 01;28(5):1050–1056.
   PubMed Web of Science ®Google Scholar